Highest-materiality recent filing
Novocure's Optune Pax receives CE Mark for locally advanced pancreatic cancer
CE Mark supported by Phase 3 PANOVA-3 trial showing statistically significant mOS improvement.
Novocure Phase 3 TRIDENT trial fails to show survival benefit for early TTFields in GBM
Median OS 17.7 mo (Early Start) vs 17.5 mo (Maintenance Start); HR 0.953, p=0.519.
Novocure Q1 net revenue $174M (+12% YoY); raises FY2026 guidance; Optune Pax launch
Net loss of $71.1M ($0.62 per share); Adjusted EBITDA of -$0.3M.
Novocure PANOVA-4 trial meets primary endpoint; DCR 74.4% vs 48% historical control in mPDAC
PANOVA-4 met primary endpoint: DCR 74.4% (N=78) vs 48% historical control (N=431), 1-sided p<0.001.
Novocure reports Q4 2025 revenues up 8% to $174M; FDA approves Optune Pax for pancreatic cancer
FDA approved Optune Pax for locally advanced pancreatic cancer in Feb 2026; expands addressable market significantly.
CMS rescinds retroactive revocation of Novocure's Medicare billing privileges
CMS revoked billing privileges retroactive to Dec 17, 2025; cited administrative re-validation issue, not substantive failure.
FDA Approves Novocure's Optune Pax for Locally Advanced Pancreatic Cancer
FDA approval based on Phase 3 PANOVA-3 trial in 571 patients with locally advanced pancreatic cancer.
NovoCure receives CMS billing revocation; expects ~$13M/month revenue impact until reinstatement
CMS revoked NovoCure's billing privileges retroactive to Dec 17, 2025 due to an administrative re-validation process issue.
NovoCure reports record FY2025 revenue $655M (+8% YoY); appoints Frank Leonard as CEO
Preliminary FY2025 net revenue $655.4M (+8% YoY); Q4 revenue $174.4M (+8% YoY).
Novocure appoints President Frank Leonard as CEO; Ashley Cordova resigns
Ashley Cordova resigned as CEO and director effective Nov 30, 2025; no disagreement related to operations.
NovoCure Q3 revenue $167M (+8% YoY), net loss $37.3M; PMA for pancreatic cancer under review
Net revenues of $167.2M, up 8% YoY; US contributed $96.6M, Germany $20.3M, France $19.6M, Japan $9.4M.
Japan MHLW approves Novocure's Optune Lua for advanced NSCLC
Japan MHLW approved Optune Lua for concurrent use with PD-1/PD-L1 inhibitors in advanced/recurrent NSCLC after platinum-based chemo.
NovoCure Q2 2025 revenue $158.8M (+6% YoY), net loss $40.1M; plans pancreatic cancer PMA in Q3
Net revenues $158.8M, up 6% YoY; net loss $40.1M ($0.36 loss per share); adjusted EBITDA -$9.9M.
Median overall survival 16.2 months with TTFields + GnP vs 14.2 months for GnP alone; HR 0.82, p=0.039.
Novocure Q1 revenue $155M (+12% YoY), net loss $34.3M; CE Mark for Optune Lua NSCLC
Revenue $155M, +12% YoY; net loss $34.3M ($0.31 loss per share); adj. EBITDA -$5.0M; cash $929M.
Novocure's Optune Lua receives CE Mark for metastatic NSCLC treatment
CE Mark for Optune Lua in mNSCLC with immune checkpoint inhibitors or docetaxel after platinum progression.
FY2024 net revenues $605.2M (+19% YoY); Q4 net revenues $161.3M (+21% YoY).
NovoCure reports preliminary FY2024 net revenues $605M (+19% YoY); Q4 $161M (+21%)
Preliminary FY2024 net revenues $605.2M (+19% YoY); Q4 $161.3M (+21% YoY).
Novocure details CEO Cordova compensation; Danziger transition terms set
Ashley Cordova named CEO effective Jan 1, 2025; base salary CHF 750K, target bonus 90% of base.
PANOVA-3 met primary endpoint: mOS 16.20 months (TTFields) vs 14.16 months (control), HR=0.819, p=0.039 (N=571).
NovoCure Q3 revenue +22% to $155M; FDA OKs Optune Lua; CEO/CFO transitions set
Q3 net revenues $155.1M (+22% YoY); net loss $30.6M ($0.28 loss per share); adjusted EBITDA $1.7M.
FDA approves Novocure's Optune Lua for metastatic NSCLC after platinum progression
Optune Lua approved for concurrent use with PD-1/PD-L1 inhibitors or docetaxel in patients with mNSCLC who progressed on/after platinum-based therapy.
NovoCure CEO Asaf Danziger to retire Jan 1, 2025; CFO Ashley Cordova appointed CEO
CEO Asaf Danziger, in role since 2002, retires Jan 1, 2025; will remain on board and advise until early 2026.
NovoCure Q2 revenue $150M (+19% YoY), net loss $33.4M, METIS trial positive
Net revenues $150.4M, up 19% YoY; U.S. contributed $95.7M, Germany $15.1M, France $14.3M.
Net revenue $138.5M (+13% YoY); net loss $38.8M ($0.36 loss per share); adjusted EBITDA -$4.6M.
TTFields + supportive care showed median time to intracranial progression of 21.9 months vs 11.3 months for supportive care alone (HR=0.67, p=0.016).
Novocure reports Q4 net loss $47.1M, full year revenue down 5%; NSCLC PMA accepted
Full year 2023 net revenues $509.3M, down 5% YoY; Q4 net revenues $133.8M, up 4% YoY.
FDA accepts Novocure's PMA for TTFields in NSCLC post-platinum; decision H2 2024
PMA application accepted for filing; FDA begins substantive review.
Final patient enrolled in global Phase 3 TRIDENT trial (950 patients) evaluating Optune Gio concurrent with radiation + temozolomide for newly diagnosed GBM.
Novocure reports preliminary 2023 revenue $509M (-5% YoY); NSCLC PMA submitted to FDA
Preliminary FY 2023 net revenues $509.3M, down 5% YoY on reduced US claim collections.
Novocure appoints Dr. Nicolas Leupin as CMO; Pritesh Shah steps down as executive officer
Dr. Nicolas Leupin appointed CMO, overseeing medical affairs, safety, and clinical development.
Novocure announces $60M cost-cutting plan, cuts 200 jobs (13% of workforce)
Reduction in residual operating expenses of ~$60M; includes 200 job cuts (13% of staff).
Novocure Q3 net revenues $127.3M (-3% YoY); net loss $49.5M as INNOVATE-3 misses endpoint
Net revenues $127.3M, down 3% YoY; US contributed $86.2M, Germany $14.7M, Japan $7.6M.
NovoCure's INNOVATE-3 trial fails primary endpoint: no OS benefit in ovarian cancer
Median OS 12.2 months (TTFields + paclitaxel) vs 11.9 months (paclitaxel alone); HR 1.008.
Novocure Q2 net revenue $126M (-11% YoY); phase 3 LUNAR NSCLC trial meets primary endpoint
Net loss $57.4M ($0.54 per share); adjusted EBITDA -$27.2M; active patients 3,571.
Novocure LUNAR phase 3 trial meets primary endpoint; median OS improved 3 months in NSCLC
LUNAR trial met primary endpoint: median OS 13.2 mo (TTFields+SOC) vs 9.9 mo (SOC alone); HR 0.74, p=0.035.
NovoCure presents positive phase 3 LUNAR trial results for TTFields in NSCLC at ASCO
Positive results from phase 3 LUNAR trial of TTFields plus standard therapies for NSCLC announced at ASCO 2023.
Phase 3 LUNAR trial meets primary endpoint: TTFields + SOC improves OS in NSCLC
Median OS 13.2 months for TTFields+SOC vs 9.9 months for SOC alone (HR 0.74, p=0.035).
Novocure Q1 2023: Revenue down 11% to $122M, net loss $53.1M, prescriptions up 8%
Total net revenues $122.2M (-11% YoY); US $85.2M, Germany $15.1M, Japan $8.7M.
Novocure LUNAR phase 3 NSCLC trial met primary endpoint; results at ASCO 2023
LUNAR trial showed statistically significant improvement in overall survival with TTFields plus standard therapies in metastatic NSCLC.
In connection with his appointment of the title "President, Novocure" on June 4, 2025 (the "Award Date"), Francis Leonard, formerly the Company's Executive Vice President, President Novocure Oncology, was awarded 179,426 Restricted Share Units
On October 30, 2024, the Company announced the appointment of Christoph Brackmann, age 51, as the Chief Financial Officer of the Novocure Group, effective January 1, 2025.
On September 3, 2024, the Company announced the appointment of Ashley Cordova, age 45, who is currently serving as the Company’s Chief Financial Officer, as the Chief Executive Officer of the Company and its respective direct and indirect subsidiaries and affiliates (together, the “Novocure Group”), effective January 1, 2025.
On September 3, 2024, the Company also announced that Wilco Groenhuysen, the Company’s Chief Operating Officer, resigned effective October 1, 2024.
On September 3, 2024, Asaf Danziger, Chief Executive Officer of NovoCure Limited (the “Company”) resigned from that position effective January 1, 2025 and accepted a new role as Senior Advisor, effective January 1, 2025.
Effective January 1, 2024, Pritesh Shah, Chief Growth Officer of the Company, resigned his position as an executive officer of the Company and agreed to become a Senior Advisor to the Chief Executive Officer, a non-executive position.
Effective January 1, 2024, the Company appointed Frank Leonard, Executive Vice President and President, Novocure Oncology.
On March 28, 2023 , the Board of Directors (the “Board”) of NovoCure Limited (the "Company") elected Kristin Stafford as a director of the Company, effective immediately, increasing the size of the Board to ten members.
On April 11, 2022, Sherilyn McCoy, a Director of NovoCure Limited (the "Company") since 2018, notified the Company of her intention not to stand for reelection to the Board of Directors of the Company (the "Board") at the Company's 2022 annual general meeting of shareholders (the "Annual Meeting"), which is currently scheduled for June 8, 2022.
Max materiality 0.90 · Median 0.72 · Most common event other_material